Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.
Journal Information
Full Title: Transl Androl Urol
Abbreviation: Transl Androl Urol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Urology & Nephrology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-772/coif). The authors have no conflicts of interest to declare."
"Funding: This study was supported by Department of Urology Grant from the Dr. George W Drach Endowment."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025